Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We exami...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Kiniwa, Yukiko, Nakamura, Kenta, Mikoshiba, Asuka, Ashida, Atsuko, Akiyama, Yasuyuki, Morimoto, Atsushi, Okuyama, Ryuhei
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7968258/
https://ncbi.nlm.nih.gov/pubmed/33731038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08016-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi